Plasma exosomal ephrin type-A receptor 2 (EphA2) levels in pancreatic cancer (PC) patients who received neoadjuvant chemotherapy or chemoradiotherapy were significantly lower before and after treatment in patients with curable PC but not in those without PC, suggesting that EphA2 could be used for monitoring the curative effect in PC [59]. The gene discussed is EPHA2; the disease is familial pancreatic carcinoma.